Gilde celebrates healthcare

GHC II was backed by current investors in Gilde Healthcare funds who have been joined by a small, select group of new investors. Investors were attracted by Gilde Healthcare Partners’ excellent investment track record, which has seen it achieve six exits in the past two years.

GHC II will continue to invest in innovative companies developing therapeutics, diagnostics, medical devices and enabling technologies. The fund will invest in all stages of a company’s development from seed stage to pre-IPO rounds. Investment size will range from €1m up to €15m per investment. The team plans to make over 15 venture investments from GHC II.

Pieter van der Meer, general partner, said: “We believe this successful fund raising reflects our high quality portfolio, which contains many of the most successful emerging healthcare companies in Europe. Our investment approach, which is not biased towards any particular country, means that we can invest in the best healthcare opportunities being created across the whole of Europe. The quality of our investment portfolio, which we have built and moved to liquidity within five years, has enabled us to generate attractive returns to our investors.”

Gilde Healthcare Partners currently has over €275m under management and is actively looking to lead new investments. Founded in 2000, the team is headquartered in Utrecht, The Netherlands, with representatives in London and Madrid. Companies that Gilde Healthcare Partners has backed include Ablynx (Belgium), Agendia (Netherlands), AMT (Netherlands), Chroma Therapeutics (UK), Glycart (Switzerland), Innate Pharma (France) and Symphogen (Denmark).